Renal insufficiency in newly-diagnosed multiple myeloma: Analysis according to international myeloma working group consensus statement

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4299-4306

  Park, Silvia ^a   Han, Boram ^a,b   Kim, Kihyun ^a   Kim, Seok Jin ^a   Jang, Jun Ho ^a   Kim, Won Seog ^a   Jung, Chul Won ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Myeloma; Renal impairment; Renal response

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; GLOMERULUS FILTRATION RATE; INCIDENCE; MIDDLE AGED; MORTALITY; MYELOMA; PATHOPHYSIOLOGY; PROGNOSIS; RENAL IMPAIRMENT; RENAL RESPONSE; VERY ELDERLY;

MYELOMA; RENAL IMPAIRMENT; RENAL RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 84908681030     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA and Drayson MT: Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23: 9219-9226, 2005.
2. Dimopoulos MA, Kastritis E, Rosinol L, Blade J and Ludwig H: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22 : 1485-1493, 2008.
3. Wirk B: Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 46 : 771-783, 2011.
4. Leung N and Behrens J: Current approach to diagnosis and management of acute renal failure in myeloma patients. Adv Chronic Kidney Dis 19 : 297-302, 2012.
5. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N and Tricot G: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 114: 822-829, 2001.
6. Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N and Mahendra P: Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 30: 471-473, 2002.
7. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K and Tricot G: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 33: 823-828, 2004.
8. Knudsen LM, Nielsen B, Gimsing P and Geisler C: Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 75: 27-33, 2005.
9. Malani AK, Gupta V and Rangineni R: Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol 116: 255-258, 2006.
10. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A and Dimopoulos MA: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92: 546-549, 2007.
11. Ludwig H, Drach J, Graf H, Lang A and Meran JG: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92: 1411-1414, 2007.
12. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA and Qazilbash MH: Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 15: 812-816, 2009.
13. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I and Zojer N: Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 28: 4635-4641, 2010.
14. Ponisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T and Niederwieser D: Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138: 1405-1412, 2012.
15. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou- Vlachou M, Terpos E and Kastritis E: The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 27: 423-429, 2013.
16. Knudsen LM, Hippe E, Hjorth M, Holmberg E and Westin J: Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 53: 207-212, 1994.
17. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C and Montserrat E: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158: 1889-1893, 1998.
18. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM and Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33, 2003.
19. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV and International Myeloma Working G: International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.
20. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG and San Miguel J: Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28: 4976-4984, 2010.
21. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N and Eknoyan G: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67: 2089-2100, 2005.
22. Knudsen LM, Hjorth M and Hippe E: Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 65: 175-181, 2000.
23. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K and Dimopoulos MA: Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 48: 337-341, 2007.
24. Alexanian R, Barlogie B and Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150: 1693-1695, 1990.
25. Oriol A: Multiple myeloma with extramedullary disease. Adv Ther 28(Suppl 7) : 1-6, 2011.
26. Calvo-Villas JM, Alegre A, Calle C, Hernandez MT, Garcia-Sanchez R and Ramirez G: Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma. Eur J Haematol 87: 281-284, 2011.
27. Krauth MT, Bankier A, Valent P, Kalhs P and Drach J: Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res 29: 1473-1477, 2005.
28. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A and Grateau G: Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79 : 319-328, 2005.
29. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K and Kohli HS: Renal involvement in multiple myeloma: a 10-year study. Ren Fail 22: 465-477, 2000.
30. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E and Dimopoulos MA: Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34 : 1395-1397, 2010.